

A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer

Submission date 29/11/2005	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 25/01/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/02/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Tim Perren

Contact details
CRUK Clinical Centre in Leeds
St James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF
+44 (0)113 206 4670
t.j.perren@leeds.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
2005-003929-22

ClinicalTrials.gov (NCT)

NCT00483782

Protocol serial number

ACTRN12607000188437

Study information

Scientific Title

A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer

Acronym

ICON7

Study objectives

To evaluate the efficacy and safety of adding bevacizumab to carboplatin and paclitaxel in patients with epithelial ovarian cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

London MREC, 14/09/2006

Study design

Randomised (1:1 basis) two-arm multicentre open-label phase III study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Epithelial ovarian cancer

Interventions

Control arm: carboplatin plus paclitaxel on day 1 every 3 weeks until disease progression or for a maximum of 6 cycles

Research arm: carboplatin plus paclitaxel on day 1 every 3 weeks until disease progression or for a maximum of 6 cycles, with bevacizumab on day 1 every 3 weeks until disease progression or for a maximum of 18 cycles

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Bevacizumab, carboplatin, paclitaxel

Primary outcome(s)

Progression-free survival (PFS)

Key secondary outcome(s)

1. Overall survival (OS)
2. Response rate
3. Duration of response
4. Toxicity
5. Quality of life (QoL)
6. Health economics
7. Translational (biomarker) research

Completion date

31/10/2008

Eligibility**Key inclusion criteria**

1. Written informed consent and able to comply with the protocol
2. Histologically confirmed:
 - 2.1. High risk International Federation of Gynaecology and Obstetrics (FIGO) stage I and II a, with grade 3 or clear cell histology, epithelial ovarian cancer
 - 2.2. FIGO stage IIb - IV (all grades, all histological types) epithelial ovarian cancer
 - 2.3. Fallopian tube or primary peritoneal cancer
3. Patients fit enough to receive protocol treatment
4. Urine dipstick for proteinuria less than 2+ (if urine dipstick is greater than or equal to 2+, 24 hour urine must demonstrate less than or equal to 1 g of protein)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Surgery (including open biopsy), or radiotherapy within the last 4 weeks prior to first dose of bevacizumab or anticipation of interval cytoreductive surgery during study treatment
2. Malignancies other than ovarian cancer within 5 years prior to randomisation, except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer
3. Uncontrolled hypertension
4. Current or recent (within 10 days of first dose of study treatment) use of aspirin greater than

325 mg/day

5. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes (except for line patency)

Date of first enrolment

01/10/2006

Date of final enrolment

31/10/2008

Locations

Countries of recruitment

United Kingdom

England

Australia

Canada

Denmark

Finland

France

Germany

New Zealand

Norway

Sweden

Study participating centre

CRUK Clinical Centre in Leeds

Leeds

United Kingdom

LS9 7TF

Sponsor information

Organisation

Medical Research Council (UK)

ROR

<https://ror.org/03x94j517>

Funder(s)

Funder type

Industry

Funder Name

F. Hoffman-La Roche

Alternative Name(s)

Hoffman-La Roche, F. Hoffmann-La Roche Ltd.

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	29/12/2011		Yes	No
Results article	results	01/08/2015		Yes	No
Results article	cost-effectiveness results	01/06/2016		Yes	No
Results article	exploratory outcome results	01/01/2019	05/02/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results				No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes

